莫西沙星对卡塔尔社区呼吸道病原体的体外活性。 - Suppr | 超能文献

In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.

作者信息

Elshafie Sittana Shamseldin, Al-Kuwari Jameela

出版信息

Int J Antimicrob Agents. 2004 Sep;24(3):309-10. doi: 10.1016/j.ijantimicag.2004.05.002.

DOI:10.1016/j.ijantimicag.2004.05.002

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.莫西沙星对卡塔尔社区呼吸道病原体的体外活性。

Int J Antimicrob Agents. 2004 Sep;24(3):309-10. doi: 10.1016/j.ijantimicag.2004.05.002.

2

Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).住院呼吸道感染患者细菌分离株的药敏模式（MOXIAKTIV研究）

Int J Antimicrob Agents. 2009 Jan;33(1):52-7. doi: 10.1016/j.ijantimicag.2008.07.017. Epub 2008 Oct 1.

3

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.ABT-492、左氧氟沙星、莫西沙星和加替沙星对三种常见呼吸道病原体的突变预防浓度。

Antimicrob Agents Chemother. 2005 Apr;49(4):1633-5. doi: 10.1128/AAC.49.4.1633-1635.2005.

4

A comparison of in vitro activity of ten oral antimicrobial agents against respiratory tract pathogens.十种口服抗菌剂对呼吸道病原体的体外活性比较。

J Chemother. 1995 Nov;7 Suppl 4:58-60.

5

Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.新型大环内酯类药物氟红霉素对流感嗜血杆菌、肺炎链球菌、化脓性链球菌、卡他莫拉菌和金黄色葡萄球菌的抗菌活性。

J Chemother. 1989 Jul;1(4 Suppl):203-4.

6

Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland.波兰社区获得性呼吸道感染主要病原体对莫西沙星及其他抗菌药物的敏感性

Int J Antimicrob Agents. 2002 Jan;19(1):47-52. doi: 10.1016/s0924-8579(01)00459-9.

7

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.加雷沙星（一种研究中的去氟（6）喹诺酮类药物）针对社区获得性呼吸道感染病原体的活性测试，包括那些氟喹诺酮类药物最低抑菌浓度（MIC）值升高或耐药的病原体。

Diagn Microbiol Infect Dis. 2007 May;58(1):9-17. doi: 10.1016/j.diagmicrobio.2007.01.020. Epub 2007 Apr 3.

8

Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.细菌呼吸道病原体的耐药性追踪：2001 - 2005年TRUST监测计划的结果总结

Postgrad Med. 2008 Sep;120(3 Suppl 1):8-15. doi: 10.3810/pgm.2008.09.suppl52.279.

9

PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.PROTEKT 1999 - 2000：日本呼吸道病原体抗菌药物敏感性多中心研究

Int J Infect Dis. 2005 Jan;9(1):27-36. doi: 10.1016/j.ijid.2004.03.008.

10

Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.抗生素耐药时代口服β-内酰胺类抗菌药物对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌呼吸道分离株的活性

Otolaryngol Head Neck Surg. 2002 Dec;127(6 Suppl):S17-23. doi: 10.1067/mhn.2002.130029.